Kiniksa Pharmaceuticals International, plc
KNSA
Rank in Stocks
#2949
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Share Price
$80.10
Market Cap
$6.25B
Change (1 day)
-3.69%
Change (1 year)
106.18%
Country
GB
Trade Kiniksa Pharmaceuticals International, plc (KNSA)
Category
Healthcare
Stock price history for Kiniksa Pharmaceuticals International, plc (KNSA)
Highest end of day price: $78.59 on 2026-10-01
Lowest end of day price: $18.08 on 2018-05-01
Lowest end of day price: $18.08 on 2018-05-01
Stock price history of Kiniksa Pharmaceuticals International, plc from 2018 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 31.68% |
| 2025 | 101.55% |
| 2024 | 16.14% |
| 2023 | 13.98% |
| 2022 | 22.63% |
| 2021 | -31.53% |
| 2020 | 57.49% |
| 2019 | -47.95% |
| 2018 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $62.20 | 65.94% |
US
|
|
| $46.29 | 38.28% |
SE
|
|
| $171.04 | 30.37% |
FR
|
|
| $116.39 | 54.38% |
US
|
|
| $59.46 | 0.32% |
IT
|
